Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
about
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatmentExpression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.MARCKS protein overexpression in inflammatory breast cancer.Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.Differential expression, localization and activity of MARCKS between mantle cell lymphoma and chronic lymphocytic leukemia.A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study."Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.(Immuno)proteasomes as therapeutic target in acute leukemia.Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.Myristoylated alanine-rich C kinase substrate (MARCKS): a multirole signaling protein in cancers.Dysregulated expression of SKP2 and its role in hematological malignancies.Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells.Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells.
P2860
Q36020972-5A429772-CB30-459A-81DD-41778C241F77Q36545784-AC1EE734-3E68-45F8-93B4-F5807F275D81Q37437254-8CB50EB6-9B7D-4B39-A006-76601E18CB3BQ37651691-0644646E-84E8-47CF-86B4-A0829267C8E3Q37688848-A784C4AD-BF3C-49C3-865E-A24691244722Q37701585-88485677-57E0-4E59-B1F4-19F4D07BB1DDQ37746021-7DE858C3-9CBE-4FA0-B3A3-719F77D2BE97Q38765422-AD11EA86-AE5F-4C81-8C4C-F330F52D0010Q38976447-FF62C67A-F2AE-4A2D-82F5-0B4692A1E8D8Q41387469-20F08172-52DD-48C5-843E-1026251E1549Q41665957-E7702FFA-9D85-4FFC-B234-54DA370B5B25Q42366169-449C4A89-8303-4A44-AE10-1D881FC0E2A7Q47131929-9BFC3A9A-1F69-499A-906C-9A84F850F874Q47181311-BD83C4A4-0A13-4C29-A225-ABCFA8E84B8AQ47642445-81B7F5B5-104A-46D2-ABE5-F3BADE84678AQ47967824-5CF32838-A1C1-4F34-B5E1-13C5ED2B2B22Q49213903-79781022-B905-4315-A716-95B6665045F5Q49462956-6E89CBF2-4E94-4A78-ADF3-3805D80D1639
P2860
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting phospho-MARCKS overc ...... al models of multiple myeloma.
@en
type
label
Targeting phospho-MARCKS overc ...... al models of multiple myeloma.
@en
prefLabel
Targeting phospho-MARCKS overc ...... al models of multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Targeting phospho-MARCKS overc ...... al models of multiple myeloma.
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2014.255
P577
2014-09-02T00:00:00Z
P6179
1019136713